{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:32:52Z","timestamp":1793147572814,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dolutegravir (DTG)\u2005+\u2005lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To investigate outcomes from other regions, we summarized real-world outcomes with DTG\u2005+\u20053TC in cohorts from Asia and South America. In this systematic literature review, relevant databases and congresses (2013\u20132023) were searched to identify non-interventional studies reporting DTG\u2005+\u20053TC use; materials reporting effectiveness, safety, or tolerability outcomes were eligible. Post hoc targeted literature searches explored newer and non-English-language materials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>From 218 publications identified, 42 representing 23,512 people using DTG\u2005+\u20053TC (naive to antiretroviral therapy (ART), n\u2005=\u2005731; switching ART, n\u2005=\u20053159; unspecified, n\u2005=\u200519,622) in China, Japan, T\u00fcrkiye, Brazil, Taiwan, Russia, Argentina, and South Korea were included. Most virologic effectiveness outcomes were reported at week 48, with virologic suppression rates ranging from 82% to 100% in people naive to ART and 86% to 100% in those switching ART. Among people initiating DTG\u2005+\u20053TC with very high (\u2265500,000 copies\/mL) baseline viral loads, 64% to 95% achieved virologic suppression at week 48. Virologic failure was infrequent. No treatment-emergent resistance was reported. Serious adverse events (1%) and discontinuations due to adverse events (2%) were infrequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In real-world cohorts across Asia and South America, initiating or switching to DTG\u2005+\u20053TC resulted in high proportions of people achieving or maintaining virologic suppression and demonstrated a good safety profile at multiple time points, consistent with clinical trial and real-world data in North America and Europe.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000043558","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T19:02:02Z","timestamp":1755543722000},"page":"e43558","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-5603","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Doblado-Maldonado","sequence":"first","affiliation":[{"name":"ViiV Healthcare, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Yit Reen","family":"Ooi","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan"},{"name":"Institute of Public Health, School of Medicine, National Yang-Ming Chiao Tung University, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"People\u2019s Hospital of Chongqing Banan District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Letang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Tres Cantos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Moorhouse","sequence":"additional","affiliation":[{"name":"ViiV Healthcare and Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Jones","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, London, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease.","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","article-title":"Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"93","author":"Swanepoel","year":"2018","journal-title":"Kidney Int"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/QAI.0000000000002629","article-title":"Human immunodeficiency virus infection and incident heart failure: a meta-analysis of prospective studies.","volume":"87","author":"Chen","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11657-021-00903-y","article-title":"People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis.","volume":"16","author":"Chang","year":"2021","journal-title":"Arch Osteoporos"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1038\/s41598-023-32965-y","article-title":"Metabolic dysfunction-associated fatty liver disease in people living with HIV.","volume":"13","author":"Michel","year":"2023","journal-title":"Sci Rep"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11892-021-01382-8","article-title":"Diabetes in people with HIV.","volume":"21","author":"Sarkar","year":"2021","journal-title":"Curr Diab Rep"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.eclinm.2022.101613","article-title":"Incidence and mortality of non-AIDS-defining cancers among people living with HIV: a systematic review and meta-analysis.","volume":"52","author":"Yuan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"e25449","DOI":"10.1002\/jia2.25449","article-title":"The challenge of HIV treatment in an era of polypharmacy.","volume":"23","author":"Back","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3851\/IMP3346","article-title":"The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.","volume":"25","author":"Baranek","year":"2020","journal-title":"Antivir Ther"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12981-020-00266-3","article-title":"Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV.","volume":"17","author":"Heron","year":"2020","journal-title":"AIDS Res Ther"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/biomedicines9030313","article-title":"Management of antiretroviral therapy with boosted protease inhibitors-darunavir\/ritonavir or darunavir\/cobicistat.","volume":"9","author":"Marin","year":"2021","journal-title":"Biomedicines"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel.","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QAD.0000000000003373","article-title":"Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV.","volume":"37","author":"Jaschinski","year":"2023","journal-title":"AIDS"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","article-title":"Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies.","volume":"52","author":"Dorjee","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection.","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial.","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","article-title":"Sustained virologic suppression with dolutegravir\/lamivudine in a test-and-treat setting through 48 weeks.","volume":"10","author":"Rolle","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/QAI.0000000000003395","article-title":"Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide-based regimen to the 2-drug regimen dolutegravir\/lamivudine in the TANGO study through week 196.","volume":"96","author":"De Wit","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial.","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review.","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions.","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"R27-20260911","first-page":"51","article-title":"Real-world clinical efficacy and safety of simplified DTG+3TC dual regimen.","volume":"35","author":"Ling","year":"2022","journal-title":"Infect Dis Info"},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/1570162X20666220514165728","article-title":"Dolutegravir plus lamivudine as initial therapy for HIV-1 infected and ARV-na\u00efve patients in West China, 24-weeks results of a preliminary real-world study.","volume":"20","author":"Hui","year":"2022","journal-title":"Curr HIV Res"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/QAI.0000000000003053","article-title":"Dolutegravir plus lamivudine dual-drug regimen in treatment-naive HIV-1-infected patients with high-level viral load: preliminary data from the real world.","volume":"91","author":"Zhao","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/QAI.0000000000003047","article-title":"Efficacy and safety of a simplified lamivudine plus dolutegravir dual therapy in HIV-1-infected patients: a multicenter cohort study in China.","volume":"91","author":"Zhong","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-20260911","first-page":"527","article-title":"Efficacy and tolerance analysis of the simplified treatment regimen of dolutegravir combined with lamivudine in patients with human immunodeficiency virus infection\/AIDS.","volume":"40","author":"Shiyun","year":"2022","journal-title":"Chin J Clin Infect Dis"},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/14787210.2022.2128766","article-title":"Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China.","volume":"20","author":"Yang","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R45-20260911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12879-021-06991-y","article-title":"Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.","volume":"22","author":"Deng","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R46-20260911","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1089\/aid.2022.0115","article-title":"Changes in inflammatory biomarkers when switching from three-drug regimens to dolutegravir plus lamivudine in people living with HIV.","volume":"38","author":"Adachi","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R56-20260911","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4314\/ahs.v22i3.46","article-title":"Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV.","volume":"22","author":"Ergen","year":"2022","journal-title":"Afr Health Sci"},{"key":"R67-20260911","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.3390\/v14112558","article-title":"Real-world effectiveness, tolerability, and safety of dolutegravir\/lamivudine in Korea.","volume":"14","author":"Lee","year":"2022","journal-title":"Viruses"},{"key":"R69-20260911","first-page":"502","article-title":"A real-world study of the simplified regimen of dolutegravir combined with lamivudine in the treatment of newly infected people with HIV.","volume":"35","author":"Li","year":"2022","journal-title":"Infect Dis Info"},{"key":"R72-20260911","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.","volume":"75","author":"Koteff","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R73-20260911","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"R74-20260911","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/QAI.0000000000002861","article-title":"Changes in serum inflammatory markers in antiretroviral therapy-naive HIV-infected patients starting dolutegravir\/lamivudine or dolutegravir\/lamivudine\/abacavir.","volume":"89","author":"Calza","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R75-20260911","doi-asserted-by":"crossref","first-page":"4","DOI":"10.24875\/AIDSRev.19000023","article-title":"Neuropsychiatric adverse events with dolutegravir and other integrase strand transfer inhibitors.","volume":"21","author":"Hoffmann","year":"2019","journal-title":"AIDS Rev"},{"key":"R80-20260911","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jgar.2022.07.022","article-title":"Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study.","volume":"31","author":"Santoro","year":"2022","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:01:33Z","timestamp":1789153293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":38,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043558","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}